Next Article in Journal
Primary Lymphoepithelioma-Like Carcinoma of Ocular Adnexa: Clinicopathologic Features and Treatment
Previous Article in Journal
Evaluation of the Clinical Benefits of Nanoparticle Albumin-Bound Paclitaxel in Women with Metastatic Breast Cancer in British Columbia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 2
10.3747/co.20.1271
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012

by
A. Mamo
1,
M. Cardoso Nogueira
1,
G. Batist
1,
M. Palumbo
1,
L. Panasci
1,
C. Ferrario
1,
P. Chaudhury
2,
P. Metrakos
2 and
P. Kavan
1,*
1
Department of Oncology, McGill University, and the Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
2
Division of General Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(2), 107-112; https://doi.org/10.3747/co.20.1271
Submission received: 2 January 2013 / Revised: 4 February 2013 / Accepted: 5 March 2013 / Published: 1 April 2013

Abstract

Background: Panitumumab is a fully human monoclonal antibody, directed against the epidermal growth factor receptor, that was shown to be effective in third-line metastatic colorectal cancer. We performed a retrospective analysis of patients with chemo-refractory non-KRAS-mutated metastatic colorectal cancer, who received panitumumab at the Jewish General Hospital in Montreal, Canada, between 2009 and 2012. Methods: This chart review included 44 patients (median age: 60 years; performance status: 0–3), of whom 50% had already received three lines of treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival and safety. Tumour progression was determined by radiologic assessments performed once every 3 months per clinical guidelines or by clinical deterioration as determined by the clinician–investigator. Results: In our sample, median PFS was 21.86 ± 5.23 weeks (95% confidence interval: 12.9 to 36.9 weeks) and overall survival was 35.14 ± 7.75 weeks (95% confidence interval: 25.6 to 73.4 weeks) with a median of 5 cycles of panitumumab treatment. The most frequently reported toxicities with panitumumab were skin toxicity (16.2% grade 3) and hypomagnesemia (10.8% grade 3). No infusion reactions were reported. Conclusions: Despite a small sample size from a single institution, our survival and efficacy data are encouraging and comparable to results obtained from the registration panitumumab trial. Our findings suggest that panitumumab can be effective and tolerable in a real-world setting.
Keywords: metastatic colorectal cancer; panitumumab; progression-free survival; overall survival; safety metastatic colorectal cancer; panitumumab; progression-free survival; overall survival; safety

Share and Cite

MDPI and ACS Style

Mamo, A.; Nogueira, M.C., 1; Batist, G.; Palumbo, M.; Panasci, L.; Ferrario, C.; Chaudhury, P.; Metrakos, P.; Kavan, P. A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012. Curr. Oncol. 2013, 20, 107-112. https://doi.org/10.3747/co.20.1271

AMA Style

Mamo A, Nogueira MC 1, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P. A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012. Current Oncology. 2013; 20(2):107-112. https://doi.org/10.3747/co.20.1271

Chicago/Turabian Style

Mamo, A., M. Cardoso Nogueira 1, G. Batist, M. Palumbo, L. Panasci, C. Ferrario, P. Chaudhury, P. Metrakos, and P. Kavan. 2013. "A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012" Current Oncology 20, no. 2: 107-112. https://doi.org/10.3747/co.20.1271

APA Style

Mamo, A., Nogueira, M. C., 1, Batist, G., Palumbo, M., Panasci, L., Ferrario, C., Chaudhury, P., Metrakos, P., & Kavan, P. (2013). A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012. Current Oncology, 20(2), 107-112. https://doi.org/10.3747/co.20.1271

Article Metrics

Back to TopTop